Osteonecrosis of the jaw induced by bisphosphonates therapy in bone metastases patient: Case report and literature review

Medication-related osteonecrosis of the jaw (MRONJ) is an increasingly common bone-related adverse event in recent years. We reported 3 bone metastases of patients who developed MRONJ after receiving bisphosphonates therapy. All patients underwent surgical necrotic bone resection combined with leukocyte and platelet-rich fibrin concentrate (L-PRF) therapy. After 6 months of follow-up, no recurrence and adverse event has been observed. This report shows that treatment with necrotic bone resection and L-PRF is an effective therapy and should be considered as an alternative treatment for the management of advanced cases of MRONJ.

Automated summary

This report presents three cases of MRONJ in patients receiving bisphosphonates therapy, who underwent necrotic bone resection and L-PRF treatment with no recurrence or adverse events observed after 6 months of follow-up. This suggests that the combination of necrotic bone resection and L-PRF may be an effective alternative treatment for advanced MRONJ cases.